2026-06-14T03:38:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/93062025-05-07T09:12:29Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968col_20.500.12105_16973

00925njm 22002777a 4500 dc Rose, Angela Mc author Kissling, Esther author Emborg, Hanne-Dorthe author Larrauri, Amparo author McMenamin, Jim author Pozo Sanchez, Francisco author Trebbien, Ramona author Mazagatos, Clara author Whitaker, Heather author Valenciano, Marta author European IVE Group author Casas Flecha, Inmaculada author 2020-03 Background: Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020. Aim: To provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings. Methods: All studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results: There were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from -58% to 57% (primary care) and -16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only). Conclusions: Influenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub)type-specific results across studies. Euro Surveill. 2020 Mar;25(10):2000153. 10.2807/1560-7917.ES.2020.25.10.2000153 1560-7917 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 32183932 http://hdl.handle.net/20.500.12105/9306 Europe Influenza Multicentre study Test-negative design Vaccine effectiveness Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020